Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $25.50.

A number of analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Scotiabank dropped their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Jefferies Financial Group dropped their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th.

Insider Buying and Selling

In related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 in the last quarter. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in KURA. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after purchasing an additional 7,722 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Kura Oncology during the 3rd quarter valued at about $298,000. Charles Schwab Investment Management Inc. boosted its position in shares of Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after purchasing an additional 14,106 shares in the last quarter. Algert Global LLC boosted its position in shares of Kura Oncology by 4.4% during the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company’s stock valued at $5,320,000 after purchasing an additional 11,493 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Kura Oncology during the 3rd quarter valued at about $596,000.

Kura Oncology Trading Down 1.9 %

KURA opened at $7.14 on Friday. The stock has a market capitalization of $576.59 million, a PE ratio of -3.03 and a beta of 0.85. The firm’s fifty day moving average price is $7.90 and its 200 day moving average price is $13.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.